Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
1.
Semin Arthritis Rheum ; 66: 152417, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38394986

RÉSUMÉ

BACKGROUND: Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3-8 % of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease. However, those factors cannot explain the entire risk of developing antimalarial retinopathy. OBJECTIVE: This study was undertaken to identify new risk factors associated with HCQ or CQ retinopathy (QRNP) in systemic lupus erythematosus (SLE) patients. METHODS: This case-control (1:2) study compared SLE patients with QRNP (cases) to those without (controls). Controls were matched for sex and known QRNP risk factors: HCQ and/or CQ treatment duration (±1 year) and age (±5 year) at SLE diagnosis. RESULTS: Forty-eight cases were compared to 96 SLE controls. Multivariable logistic-regression analysis retained the following as independent determinants significantly associated with QRNP: concomitant selective serotonin-reuptake inhibitor (SSRI) or serotonin- and norepinephrine-reuptake inhibitor (SNRI) intake (OR [95 % confidence interval] 6.6 [1.2 to 40.9]; p < 0.01); antiphospholipid syndrome (OR=8.9 [2.2 to 41.4] p < 0.01); blood hydroxychloroquine/desethylchloroquine concentration ([HCQ]/[DCQ]) ratio <7.2 (OR 8.4 [2.7 to 30.8]; p < 0.01) or skin phototype ≥4 (OR 5.5 [1.4 to 26.5]; p = 0.02), but not daily HCQ dose, blood [HCQ] or body mass index. CONCLUSION: The results of this case-control study identified blood [HCQ]/[DCQ] ratio, concurrent SSRI/SNRI therapy, skin phototype ≥4 and antiphospholipid syndrome as new risk factors for QRNP.


Sujet(s)
Antirhumatismaux , Chloroquine , Hydroxychloroquine , Lupus érythémateux disséminé , Rétinopathies , Humains , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/usage thérapeutique , Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/complications , Lupus érythémateux disséminé/induit chimiquement , Femelle , Chloroquine/effets indésirables , Chloroquine/usage thérapeutique , Rétinopathies/induit chimiquement , Facteurs de risque , Mâle , Adulte , Études cas-témoins , Adulte d'âge moyen , Antirhumatismaux/effets indésirables , Antipaludiques/effets indésirables , Antipaludiques/usage thérapeutique
2.
Saudi J Kidney Dis Transpl ; 31(1): 182-190, 2020.
Article de Anglais | MEDLINE | ID: mdl-32129212

RÉSUMÉ

Glomerulonephritis associated with anti-neutrophil cytoplasmic antibody (ANCA) vasculitis still has a high prevalence of end-stage renal disease (ESRD), particularly in patients with advanced renal failure at presentation. This study aims to evaluate the clinical and histo- pathological features of renal involvement and investigate factors associated with ESRD. Patients with renal biopsy-proven ANCA-associated glomerulonephritis were included retrospectively over a period of nine years (June 2007 to March 2016). The renal survival, defined as time to reach ESRD, was evaluated based on clinical parameters, histopathological classification, and renal risk score. A total of 37 patients with crescentic glomerulonephritis were included in the study. The average age was 54 ± 16 years (range: 17-80) and 51.3% were female. Twenty-two patients were diagnosed with microscopic polyangiitis and 15 had granulomatosis with polyangiitis. The median glomerular filtration rate at presentation was 16.73 mL/min/1.73 m2. Thirty-five patients (94.5%) had renal failure at presentation and 23 patients (62.1%) required initial hemodialysis (HD) therapy. The pattern of glomerular injury was categorized as sclerotic in 48.6% of cases, crescentic in 24.3%, mixed in 24.3%, and focal class in 2.7%. Regarding renal risk score, we had five patients with low risk, 17 with intermediate risk and 15 with high risk. ESRD occurred in 47% of intermediate-risk group and 66% of the high risk group. During follow-up, 17 patients (45.9%) developed ESRD. Tobacco addiction (P = 0.02), alveolar hemorrhage (P = 0.04), hypertension (P = 0.04), initial HD (P = 0.04), and sclerotic class (P = 0.004) were associated with ESRD. In our patients, a sclerotic class was associated with a higher risk of ESRD, suggesting that histo- pathological classification is potentially an important parameter to predict outcomes in renal disease secondary to ANCA-associated vasculitis.


Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles , Glomérulonéphrite , Défaillance rénale chronique , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Femelle , Débit de filtration glomérulaire , Humains , Rein/anatomopathologie , Rein/physiopathologie , Mâle , Adulte d'âge moyen , Études rétrospectives , Résultat thérapeutique , Jeune adulte
3.
Saudi J Kidney Dis Transpl ; 28(5): 1184-1187, 2017.
Article de Anglais | MEDLINE | ID: mdl-28937084

RÉSUMÉ

Ocular and oral dryness are the hallmark of Sjögren's syndrome (SS). However, SS can be associated with a variety of complications, affecting organs such as the liver, kidneys, lungs, muscle, and nervous system. Renal involvement has been usually in the form of tubulointerstitial nephritis. However, glomerulonephritis is rare in primary SS. We report three clinical cases of SS with anti-neutrophil cytoplasmic antibody-mediated crescentic glomerulo-nephritis treated with prednisone and cyclophosphamide, with favorable outcome.


Sujet(s)
Anticorps anti-cytoplasme des polynucléaires neutrophiles/immunologie , Glomérulonéphrite/immunologie , Syndrome de Gougerot-Sjögren/immunologie , Sujet âgé , Cyclophosphamide/usage thérapeutique , Femelle , Glomérulonéphrite/diagnostic , Glomérulonéphrite/traitement médicamenteux , Glucocorticoïdes/usage thérapeutique , Humains , Immunosuppresseurs/usage thérapeutique , Adulte d'âge moyen , Prednisone/usage thérapeutique , Syndrome de Gougerot-Sjögren/complications , Syndrome de Gougerot-Sjögren/diagnostic , Syndrome de Gougerot-Sjögren/traitement médicamenteux , Résultat thérapeutique
4.
Ann Saudi Med ; 35(4): 327-30, 2015.
Article de Anglais | MEDLINE | ID: mdl-26497716

RÉSUMÉ

Pleural myelomatous involvement in multiple myeloma (MM) is rare, occurring in less than 1% of cases. We retrospectively studied five cases of patients with MM who developed myelomatous pleural effusions. Three men and 2 women with a mean age of 61 years presented with myelomatous pleural effusion. The pleural fluid electrophoresis revealed a peak of IgG in three cases, of IgA in one case, and of lambda light chains in one case, which were identical to that in the sera of the patients. Detection of typical plasma cells in pleural fluid cytology was contributive, and histologic confirmation by pleural biopsy was positive in four cases. Treatment consisted of chemotherapy. The clinical outcome was initially good, but relapses occurred in all cases early and were complicated by fatal infections. Myelomatous pleural effusion is a rare affection. It is usually a late complication associated with poor prognosis.


Sujet(s)
Myélome multiple/complications , Épanchement pleural malin/anatomopathologie , Sujet âgé , Biopsie , Électrophorèse , Issue fatale , Femelle , Humains , Immunoglobuline A/métabolisme , Immunoglobuline G/métabolisme , Chaines lambda des immunoglobulines/métabolisme , Mâle , Adulte d'âge moyen , Myélome multiple/traitement médicamenteux , Myélome multiple/anatomopathologie , Récidive tumorale locale/complications , Récidive tumorale locale/mortalité , Épanchement pleural malin/traitement médicamenteux , Épanchement pleural malin/étiologie , Appareil respiratoire/métabolisme , Appareil respiratoire/anatomopathologie , Études rétrospectives
5.
Presse Med ; 38(3): 362-5, 2009 Mar.
Article de Français | MEDLINE | ID: mdl-19135845

RÉSUMÉ

PURPOSE: Our study sought to determine the frequency and clinical and immunologic characteristics of pericarditis in patients with systemic lupus erythematosus (SLE). METHODS: We retrospectively analyzed the files of all patients with SLE diagnosed between 1987 and 2005. The study included only those patients who had undergone echocardiography. They were divided in two groups according to whether or not they had pericarditis, and their clinical and immunologic characteristics and outcome were compared. RESULTS: Our records found 180 patients with SLE, 97 of whom had had echocardiography. The frequency of pericarditis was 39%. The average age of the 34 women and 4 men with pericarditis at its onset was 36.4 years. There were 59 SLE patients without pericarditis, 56 women and 3 men with an average age of 28.8 years. Pericarditis was frequently associated with pleural effusions. The prevalence of anticardiolipin antibodies was significantly lower in the group of patients with pericarditis. CONCLUSION: Pericarditis is the most common cardiac manifestation in SLE. Its frequency in this sample of Tunisian patients was similar to that described in different ethnic groups. The association between pericarditis and pleuritis is standard. Anticardiolipin antibodies, commonly positive in valve diseases, were less frequent in our patients with pericarditis.


Sujet(s)
Lupus érythémateux disséminé/complications , Péricardite/épidémiologie , Péricardite/immunologie , Adulte , Âge de début , Anticorps anticardiolipines/immunologie , Échocardiographie , Femelle , Humains , Mâle , Péricardite/imagerie diagnostique , Péricardite/étiologie , Prévalence , Études rétrospectives , Tunisie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...